Genelux Corporation — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Genelux is a clinical-stage biopharmaceutical company developing oncolytic viral cancer immunotherapies, led by Olvi-Vec. It has no products approved for sale; reported revenue is not product-sale revenue. Financial amounts below are in millions of dollars unless otherwise indicated.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $0.170 | $0 |
| Research and development expense | $2.845 | $2.369 |
| General and administrative expense | $3.787 | $1.095 |
| Operating loss | $6.462 | $3.464 |
| Net loss | $10.364 | $3.801 |
| Basic and diluted loss per share | $0.53 | $0.42 |
| Cash used in operating activities | $4.590 | Cash provided: $2.825 |
| Cash and cash equivalents, March 31 | $10.338 | — |
The $170,000 revenue was recognized when product previously supplied for Newsoara’s clinical trials was shipped; it had been collected and recorded as deferred revenue in 2022. The company reported no commercial product revenue. Operating margins are not meaningful given the small, non-product revenue base and continuing development-stage losses.
At March 31, total assets were $14.616 million, total liabilities $11.925 million, and shareholders’ equity $2.691 million, versus a $35.783 million shareholders’ deficit at December 31, 2022. Current assets were $12.056 million and current liabilities $10.543 million. Cash increased from $0.397 million at year-end, largely reflecting IPO proceeds. The filing reports no material off-balance-sheet arrangements.
Operating cash use was partly offset in the cash-flow reconciliation by substantial noncash expenses, including stock-related compensation, debt-discount amortization, and warrant-related charges. Investing cash use was $0.109 million. Financing provided $14.640 million, including $14.503 million of IPO cash proceeds and $0.900 million of shareholder-note proceeds, partly offset by repayments and offering costs.
Changes from the prior comparable period and unusual items
- Net loss increased $6.563 million year over year. Operating expenses rose $3.168 million; G&A increased 246%, principally due to stock compensation and public-company legal and professional costs.
- Other expenses rose to $3.902 million from $0.337 million, including $3.110 million of financing costs for warrants issued in connection with conversions of debt and $0.649 million of debt-discount amortization.
- The company completed its IPO in January 2023, selling 2.653 million shares at $6.00 per share and receiving approximately $12.632 million in net proceeds. Preferred shares, most convertible notes and accrued amounts, and preferred dividends converted into common equity. Convertible debt fell from $15.407 million of shareholder notes and $8.524 million net notes payable at year-end to no long-term convertible notes and $0.065 million of current convertible principal at March 31.
- Common shares outstanding increased to 24.553 million at March 31 from 9.127 million at December 31. The company also recorded $2.606 million of Q1 stock-option repricing cost; options covering 4.093 million shares were repriced to $6.00, including 2.796 million shares held by executive officers and directors.
Outlook, risks and contingencies
Management and the financial statements identify substantial doubt about the company’s ability to continue as a going concern, reflecting recurring losses, $4.590 million of quarterly operating cash use, and a $203.591 million accumulated deficit. The independent auditor had also raised substantial doubt in its 2022 report. The company says March 31 cash plus proceeds from its announced private placement are expected to fund operations through the first quarter of 2025; that estimate depends on assumptions and financing completion and timing.
On May 12, 2023, after quarter-end, Genelux agreed to sell 1,665,213 shares at $20 per share in a private placement expected to generate approximately $33.3 million gross, including approximately $1.5 million from cancellation of bridge loans and accrued interest. Up to $15 million of investor commitments is to be funded after the initial closing, no later than November 15, 2023. These proceeds were not included in March 31 cash. The filing also says a $0.210 million bridge loan was repaid after quarter-end and warrants for 111,828 shares were exercised for $1.174 million.
Management expects losses and expenses to rise as it advances Olvi-Vec and other programs, conducts trials, develops manufacturing capacity, and operates as a public company. The filing gives no financial performance guidance. Principal risks include clinical efficacy, safety and enrollment; regulatory review; manufacturing-process comparability and supply; reliance on collaborators and vendors; intellectual-property protection; and the need for further capital, which may be unavailable or dilutive. COVID-19 had no material net impact on Q1 results, but affected supply-chain conditions and could disrupt sites or development timelines.
In April 2023, Newsoara began a Phase 1/2 Olvi-Vec trial in recurrent small cell lung cancer in China. The first participant experienced impaired liver function, coagulation disorder, low platelets, increased blood amylase and fever, subsequently recovered, remained on trial and received scheduled chemotherapy. Newsoara planned to continue with de-escalated dose cohorts; Genelux said it did not expect an impact on U.S. trials. Genelux reported one pending litigation and did not believe its outcome was reasonably likely to materially adversely affect its business or financial results. Disclosure controls were judged effective at a reasonable-assurance level; the filing did not include management’s internal-control-over-financial-reporting assessment during the new-public-company transition period.
Important facts for investors to verify
- Whether the private placement closed as expected, when the deferred investor funding is received, and how proceeds and loan cancellations compare with the announced terms.
- Cash burn, updated operating runway and financing needs against management’s first-quarter-2025 runway estimate.
- Olvi-Vec clinical progress, including the PRROC Phase 3 trial, the expected final long-term Phase 2 readout, and any further safety information from the China SCLC trial.
- Manufacturing comparability and regulatory status of the company’s newer mammalian-cell production process, and whether it affects trial execution or supply.
- Subsequent share issuance, warrant exercises, option repricing and potential dilution, including the scheduled IPO lock-up expiration in July 2023.
- Terms and developments in the pending litigation and any changes to the company’s going-concern assessment.